Introduced
Underlined text would be added to current law. Struck-through text would be removed.
| By: Menéndez | S.B. No. 336 | |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to health benefit plan coverage of treatments for | |
| pediatric neuroinflammatory disorder. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. Chapter 1367, Insurance Code, is amended by | |
| adding Subchapter H to read as follows: | |
| SUBCHAPTER H. PEDIATRIC NEUROINFLAMMATORY DISORDERS | |
| Sec. 1367.351. DEFINITIONS. In this subchapter: | |
| (1) "Off-label use" means the use of a prescription | |
| drug or therapy approved for use by the United States Food and Drug | |
| Administration in a manner other than the approved use. | |
| (2) "Pediatric neuroinflammatory disorder" means an | |
| immune-mediated inflammatory condition affecting the central | |
| nervous system in an individual younger than 18 years of age, | |
| including but not limited to autoimmune encephalitis, | |
| post-infectious encephalitis, acute disseminated | |
| encephalomyelitis (ADEM), optic neuritis, transverse myelitis, | |
| neuromyelitis optica spectrum disorder (NMOSD), pediatric | |
| acute-onset neuropsychiatric syndrome (PANS), pediatric autoimmune | |
| neuropsychiatric disorders associated with streptococcal | |
| infections (PANDAS), and other clinically recognized neuroimmune | |
| or neuroinflammatory disorders diagnosed by a physician using | |
| accepted clinical criteria, diagnostic testing, and clinical | |
| judgment. | |
| Sec. 1367.352. APPLICABILITY OF SUBCHAPTER. (a) This | |
| subchapter applies only to a health benefit plan that provides | |
| benefits for medical, surgical, or prescription drug expenses | |
| incurred as a result of a health condition, accident, or sickness, | |
| including an individual, group, blanket, or franchise insurance | |
| policy or insurance agreement, a group hospital service contract, | |
| or an individual or group evidence of coverage or similar coverage | |
| document that is issued by: | |
| (1) an insurance company; | |
| (2) a group hospital service corporation operating | |
| under Chapter 842; | |
| (3) a health maintenance organization operating under | |
| Chapter 843; | |
| (4) an approved nonprofit health corporation that | |
| holds a certificate of authority under Chapter 844; | |
| (5) a multiple employer welfare arrangement that holds | |
| a certificate of authority under Chapter 846; | |
| (6) a stipulated premium company operating under | |
| Chapter 884; | |
| (7) a fraternal benefit society operating under | |
| Chapter 885; | |
| (8) a Lloyd's plan operating under Chapter 941; or | |
| (9) an exchange operating under Chapter 942. | |
| (b) Notwithstanding any other law, this subchapter applies | |
| to: | |
| (1) a basic coverage plan under Chapter 1551; | |
| (2) a basic plan under Chapter 1575; and | |
| (3) a primary care coverage plan under Chapter 1579. | |
| Sec. 1367.353. COVERAGE REQUIRED. (a) A health benefit | |
| plan must provide coverage for the treatment of pediatric | |
| neuroinflammatory disorder if: | |
| (1) that condition was diagnosed by a physician with | |
| appropriate specialty training, including neurology, pediatric | |
| neurology, pediatric immunology, pediatric rheumatology, and an | |
| equivalent specialty, based on accepted clinical criteria, | |
| diagnostic testing, and the physician's clinical judgment; | |
| (2) the treatment is prescribed by the enrollee's | |
| treating physician as medically necessary for an individual | |
| diagnosed with that condition; and | |
| (3) the enrollee's treating physician documents, in | |
| the enrollee's medical record, the clinical rationale for the | |
| treatment and the basis for the diagnosis of that condition. | |
| (b) The coverage required by this section must include | |
| coverage of: | |
| (1) the following treatments: | |
| (A) immunomodulating therapies, including: | |
| (i) intravenous immunoglobulin therapy; | |
| (ii) rituximab; | |
| (iii) therapeutic plasma exchange; | |
| (iv) cyclophosphamide; | |
| (v) mycophenolate mofetil; | |
| (vi) azathioprine; and | |
| (vii) other disease-modifying therapies | |
| used to treat pediatric neuroinflammatory disorder under accepted | |
| clinical practices; | |
| (B) antibiotics; and | |
| (C) behavioral therapy; | |
| (2) costs related to inpatient or outpatient | |
| administration of a treatment described by Subdivision (1), | |
| including infusion services; and | |
| (3) any other costs associated with administering a | |
| treatment described by Subdivision (1), including clinical | |
| monitoring, laboratory testing, imaging, and other ancillary | |
| services. | |
| (c) In determining whether a treatment is medically | |
| necessary under this section, a health benefit plan issuer shall | |
| give substantial deference to the clinical judgment of the | |
| enrollee's treating physician who has appropriate experience in | |
| diagnosing or treating pediatric neuroimmune or neuroinflammatory | |
| disorders, taking into consideration the enrollee's clinical | |
| presentation, diagnostic findings, treatment history, and response | |
| to previous treatment. | |
| Sec. 1367.354. APPROVAL OF TREATMENT. A health benefit | |
| plan issuer may not deny or delay approval of a treatment for which | |
| coverage is required under Section 1367.353 on the sole basis that: | |
| (1) the treatment is prescribed for an off-label use | |
| or is classified by the health benefit plan issuer as experimental | |
| or investigational, if the treatment is medically necessary and | |
| supported by peer-reviewed medical literature, recognized clinical | |
| practice guidelines, or other generally accepted medical evidence | |
| applicable to the enrollee's condition; | |
| (2) the enrollee has previously received the same | |
| treatment for pediatric neuroinflammatory disorder or another | |
| diagnosis; or | |
| (3) the enrollee's diagnosis is listed under a | |
| diagnostic code or label other than pediatric neuroinflammatory | |
| disorder. | |
| Sec. 1367.355. LIMIT ON COST-SHARING REQUIREMENT. A health | |
| benefit plan issuer may not impose a cost-sharing requirement, | |
| including a copayment, coinsurance cost, or deductible for a | |
| treatment required to be covered under Section 1367.353 that is | |
| greater than the cost-sharing requirement applied to other covered | |
| health care services within the same benefit tier under the | |
| enrollee's health benefit plan. | |
| Sec. 1367.356. PROHIBITION ON MULTIPLE PREAUTHORIZATIONS. | |
| For purposes of this section, a subsequent prescription, treatment | |
| order, infusion, or administration of the same treatment during the | |
| applicable 12-month period does not constitute a new treatment | |
| requiring additional preauthorization solely because the treatment | |
| is prescribed or administered in separate doses or courses, | |
| provided the treatment remains medically necessary for the covered | |
| condition under Section 1367.353. | |
| Sec. 1367.357. REPORTING. (a) The department shall: | |
| (1) collect data on any denial or appeal of a denial of | |
| a treatment required to be covered under Section 1367.353; and | |
| (2) annually submit to the legislature a written | |
| report summarizing the data collected under Subdivision (1). | |
| (b) The department may require a health benefit plan issuer | |
| to submit data to the department in the form and manner prescribed | |
| by the commissioner for purposes of complying with this subchapter. | |
| SECTION 2. The changes in law made by this Act apply only to | |
| a health benefit plan that is delivered, issued for delivery, or | |
| renewed on or after January 1, 2028. | |
| SECTION 3. This Act takes effect September 1, 2027. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.